Related Experiment Video

Updated: Jun 4, 2026

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand

De-chun Geng1, Yao-zeng Xu, Hui-lin Yang

  • 1Department of Orthopaedic Surgery, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

Chinese Medical Journal
|March 3, 2011
PubMed
Abstract

Insights

The CB2 antagonist AM630 inhibits osteoclast formation by suppressing RANKL-induced signaling. This finding highlights CB2 receptor

Area of Science:

  • Bone biology and pharmacology
  • Cell signaling pathways
  • Osteoclast differentiation mechanisms

Background:

  • Cannabinoid receptor 2 (CB2) plays a role in bone remodeling.
  • CB2 selective antagonist AM630 effects on osteoclastogenesis were investigated.
  • Understanding CB2's role in bone health is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the effects of CB2 antagonist AM630 on receptor activator of nuclear factor kappa B (RANKL) induced osteoclast differentiation.
  • To elucidate the underlying signaling pathway involved in CB2-mediated osteoclastogenesis.

Main Methods:

  • RAW264.7 cells were treated with RANKL and AM630.
  • Osteoclast formation was assessed by tartrate-resistant acid phosphatase (TRAP) staining.
  • Gene expression (RANK, cathepsin K, NF-κB) and protein levels (ERK, P-ERK, NF-κB) were analyzed using RT-PCR and Western blotting.

Main Results:

  • AM630 did not affect RAW264.7 cell viability.
  • AM630 dose-dependently inhibited osteoclast formation and TRAP-positive cells.
  • AM630 suppressed RANK and cathepsin K gene expression and inhibited RANKL-induced ERK activation, but not NF-κB activation.

Conclusions:

  • AM630 effectively inhibits osteoclastogenesis induced by RANKL in RAW264.7 cells.
  • The mechanism involves the suppression of ERK signaling pathway.
  • CB2 receptor modulation presents a potential therapeutic strategy for bone remodeling disorders.

More Related Videos

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro07:51

Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro

Published on: March 18, 2019

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...